1Y Close · As of Aug 26, 2026
ISU Abxis operates in the Pharmaceuticals sector.
Legal name: ISU Abxis Co., Ltd.
In fiscal year 2025, ISU Abxis (086890) reported revenue of 56.7 billion KRW, down 6.0% from 60.3 billion KRW a year earlier.
Operating profit was 1.6 billion KRW and net income was -10.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 139.9 billion KRW, with a P/B of 1.22.
These figures can be verified in the DART filing (receipt no. 20260312001420).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 56.7B | 1.6B | -10.7B |
| 2024 | 60.3B | 13.4B | 14.7B |
| 2023 | 54.3B | 3.9B | 3.6B |
Recent Filings
Semi-Annual Report (2026.06)
Corporate Briefing (IR)
Operating (Preliminary) Earnings (Fair Disclosure)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-10 | Corporate Briefing (IR) |
| 2026-08-06 | Operating (Preliminary) Earnings (Fair Disclosure) |